Sodium butyrate, a supplement form of a fiber-derived compound made by gut bacteria, reduced fat buildup and improved insulin response in liver cells and mice with fatty liver disease, according to Gram Research analysis of a 2026 study. Because these findings come from cells and animals, human benefits remain unproven.
Fatty liver disease, now called MASLD, is a growing health problem linked to blood sugar issues and inflammation. A 2026 study tested sodium butyrate, a supplement form of a fiber-derived compound made by gut bacteria. In liver cells exposed to fat, sodium butyrate reduced fat buildup, improved sugar uptake, and lowered inflammatory signals. In mice fed a high-fat diet, it slowed weight gain, reduced liver fat, and improved how well the body responded to insulin. According to Gram Research analysis, these results are promising, but they come from lab cells and animals. Human studies are needed before anyone can know whether sodium butyrate helps people with fatty liver disease.
Key Statistics
A 2026 study published in Frontiers in Bioscience found that mice fed a high-fat diet for 16 weeks and then given sodium butyrate for 8 weeks showed reduced liver fat and improved insulin sensitivity.
In a 2026 study using fat-treated liver cells, sodium butyrate lowered the release of four inflammatory chemicals, TNF-α, IL-6, IL-1β, and MCP-1, in a dose-dependent manner.
The 2026 study tested sodium butyrate in HepG2 liver cells and C57BL/6 mice, and its results have not yet been confirmed in human trials.
The Quick Take
- What they studied: Researchers asked whether sodium butyrate, a supplement form of a compound gut bacteria make from fiber, could improve fatty liver disease and insulin resistance, and how it might work in the body.
- Who participated: The study used two groups: liver cells grown in a lab dish (HepG2 cells) and male and female mice of one common lab strain (C57BL/6). The paper does not report a total number of participants or animals.
- Key finding: Sodium butyrate reduced fat buildup in liver cells and in mice, lowered inflammation markers, and improved blood sugar control. Changes in liver cells were dose-dependent, meaning larger doses produced larger effects, within the limits tested.
- What it means for you: This research is early and comes from cells and animals, so it cannot show that sodium butyrate helps people. If you have fatty liver disease or blood sugar concerns, talk with your doctor before trying any supplement.
The Research Details
The researchers worked in two parts. First, they treated liver cells in a lab dish with palmitate, a common saturated fat, to make the cells fat-laden and resistant to insulin. They then added sodium butyrate at several doses and measured fat storage, sugar uptake, stored sugar (glycogen), gene activity, and inflammatory chemicals released by the cells.
Second, they fed mice a high-fat diet for 16 weeks to cause fatty liver disease. After that, some mice received sodium butyrate by mouth for 8 more weeks while the diet continued. The team checked body weight, blood fat levels, liver fat, blood sugar tolerance, insulin response, and immune cells in the liver. They also looked at two cell-signaling pathways, AMPK and PI3K/AKT, which help control how the body burns fat and uses sugar.
The study also used RNA sequencing, a method that reads which genes are switched on or off, to see how sodium butyrate changed gene activity in the liver.
Using both cells and whole animals is a useful approach. Cell studies show what happens at the level of individual liver cells, while mouse studies show whether effects appear in a living body with a full digestive system, immune system, and hormone system. Seeing results in both settings makes the findings more believable than either approach alone.
Still, the mouse diet and the cell model are simplified versions of human fatty liver disease. Results in these models do not always carry over to people, so the findings are best seen as a starting point for further research.
The study used a controlled design, with comparison groups, standard lab methods, and several different tests that pointed in the same direction. Using multiple measurement methods strengthens confidence in the results.
However, the paper does not clearly report the number of animals or cell experiments in each group, which makes it harder to judge statistical strength. The authors also state that further mechanism studies and human research are still needed. This is preclinical research, which is an early stage of science and is not yet proof of a human treatment.
What the Results Show
In liver cells exposed to palmitate, sodium butyrate reduced the amount of fat stored inside the cells. The cells also took up sugar more effectively and stored more glycogen, which is the form of sugar the liver keeps for later use. These changes appeared more strongly as the dose increased.
The treated cells also released fewer inflammatory chemicals. The researchers measured four of them: TNF-α, IL-6, IL-1β, and MCP-1. These chemicals help signal inflammation, and high levels are linked to liver damage over time. Lower levels suggest that sodium butyrate may calm the inflammatory response, although the study did not test whether this prevents liver damage in people.
In mice fed a high-fat diet, sodium butyrate reduced weight gain and improved blood fat levels. Liver fat was lower, and the mice handled sugar better in glucose tolerance tests. Their bodies also responded better to insulin, a hormone that helps move sugar out of the blood and into cells.
The researchers also found that sodium butyrate lowered inflammatory chemicals in the blood and liver, and reduced a marker called F4/80, which indicates the presence of certain immune cells in the liver. This suggests fewer immune cells were moving into liver tissue. The authors linked these effects to changes in the AMPK and PI3K/AKT pathways, though they noted that how these pathways interact still needs more study.
The study pointed to a possible signaling route involving GPR43, a receptor that detects short-chain fats, followed by CaMKK2, AMPKα, and SIRT1. Restoring this route appeared to lower fat production and increase fat burning inside liver cells. This helps explain how sodium butyrate may work, but it does not prove the route is the only cause of the effects.
The RNA sequencing results showed that sodium butyrate changed the activity of many genes involved in fat and sugar handling, and in inflammation. Fewer genes that push the liver toward making sugar were active, which fits with better blood sugar control. These gene-level changes give a clearer picture of the biology, but they need confirmation in other studies.
Butyrate and related short-chain fats have been studied for years for their roles in gut health, inflammation, and metabolism. Earlier research has linked these fats to better insulin sensitivity and lower liver fat in some animal models, so this study fits with a growing body of work. What is new here is the focus on liver fat, insulin resistance, and two specific signaling pathways working together.
Many earlier studies of butyrate have used different forms, doses, and diets, so the results across studies are not always easy to compare. Gram Research analysis suggests the evidence is consistent in animals but still limited in humans.
The most important limitation is that this research used cells and mice, not people. Mouse fatty liver disease is not identical to human fatty liver disease, and what works in mice does not always work in humans.
The paper also does not state the total number of animals or experiments, which makes it harder to judge how reliable the numbers are. The authors acknowledge that the exact way the two signaling pathways interact is still unclear, and that more work is needed on inflammation and translation to people.
Finally, the study does not show how much sodium butyrate would be safe or effective for humans, how long benefits might last, or whether it would work alongside other treatments.
The Bottom Line
Based on this single preclinical study, the findings are promising but early. Confidence that sodium butyrate helps fatty liver disease in people is low at this stage. Confidence that the compound affects liver fat, inflammation, and sugar handling in these lab models is moderate, since several measures point the same way. People should not start sodium butyrate supplements based on this study alone. Eating more fiber, staying active, limiting added sugar, and following medical advice remain the best-supported steps for liver and blood sugar health.
Researchers studying liver disease, metabolism, and gut health should pay close attention, as should clinicians who follow emerging treatment ideas. People living with fatty liver disease or insulin resistance may find the topic interesting, but they should discuss any supplement with a doctor first. Healthy adults without liver or blood sugar concerns do not need to act on this research. Anyone who is pregnant, has kidney or liver disease, or takes medications should speak with a healthcare provider before taking sodium butyrate.
Human trials usually take several years to design, run, and publish, so practical treatments based on this work are likely far off. Even if the compound later shows promise in people, researchers would need to test safety, dosing, and long-term effects. Anyone wanting to improve liver health now can expect changes from proven habits, such as weight management and regular activity, to appear over weeks to months, and the most meaningful liver changes often take several months of consistent effort.
Frequently Asked Questions
Does sodium butyrate help fatty liver disease?
A 2026 study found sodium butyrate reduced liver fat and improved insulin response in mice and liver cells. These results are preclinical, so it is not yet known whether sodium butyrate helps people with fatty liver disease. Anyone with liver concerns should consult a doctor first.
What is sodium butyrate and where does it come from?
Sodium butyrate is a supplement form of butyrate, a short-chain fat that gut bacteria produce when they digest dietary fiber. In the 2026 study, researchers gave it to mice by mouth and added it to liver cells to observe its effects on fat and sugar handling.
Can sodium butyrate lower inflammation in the liver?
In a 2026 study, sodium butyrate lowered four inflammatory chemicals in fat-treated liver cells and reduced inflammatory signals in mice. Researchers noted these effects in lab and animal models only, and more work is needed to confirm whether this protects human livers.
Should I take sodium butyrate supplements for insulin resistance?
The current evidence comes only from lab cells and mice, so it does not support taking sodium butyrate for insulin resistance. Proven steps include eating more fiber, staying active, and limiting added sugar. Discuss any supplement with your healthcare provider before starting.
Want to Apply This Research?
- Track weekly averages of fiber grams eaten per day, added sugar grams, and minutes of moderate activity. If you are working with your doctor on liver or blood sugar goals, also log fasting blood glucose or waist measurements at the same time each week.
- Use the app to set one realistic goal, such as adding one high-fiber food, like beans, oats, or vegetables, to each meal. Track it daily for two weeks, then review progress. Do not start a sodium butyrate supplement based on this research without medical guidance.
- Review trends monthly rather than daily, focusing on fiber intake, sugar intake, activity minutes, and weight changes. Share the logged data at routine medical visits so your care team can see the full picture. If your doctor requests liver tests or blood sugar checks, record those results in the app to track changes over time.
This article summarizes a preclinical study conducted in liver cells and mice and has not been tested in humans. The findings do not establish safety or effectiveness of sodium butyrate for people. This content is for general education only and is not medical advice. Consult a qualified healthcare provider before making any changes to your diet, supplements, or treatment for liver or blood sugar conditions.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.